You can buy or sell BEAM and other stocks, options, ETFs, and crypto commission-free!
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. Read More The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
— per share
Expected Nov 12, Pre-Market